The phase III KEYNOTE-204 trial evaluating Keytruda in adult patients with relapsed or refractory classical Hodgkin lymphoma met one of its dual primary endpoints of progression-free survival.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe